| Dr Priya V Rajan, MD | |
|
1025 Morehead Medical Dr, Suite 500, Charlotte, NC 28204-2963 | |
| (704) 446-1544 | |
| Not Available |
| Full Name | Dr Priya V Rajan |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 23 Years |
| Location | 1025 Morehead Medical Dr, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528136843 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VM0101X | Obstetrics & Gynecology - Maternal & Fetal Medicine | 200801459 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwestern Memorial Hospital | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwestern Medical Faculty Foundation | 4587576814 | 3255 |
News Archive
A team of Italian scientists reported this week that blocking the interaction between urokinase receptor (uPAR) and formyl peptide receptor type 1 (FPR1) suppresses the ability of melanoma cells to migrate, invade through an extracellular matrix, and to burrow through a layer of endothelial cells.
Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda's screening assay for the early detection of cancer
Research by a team of scientists from Cologne, Munich and Mainz has shown an unprecedented degree of connectivity reorganization in newly-generated hippocampal neurons in response to experience, suggesting their direct contribution to the processing of complex information in the adult brain.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
› Verified 7 days ago
| Entity Name | Northwestern Medical Faculty Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346235314 PECOS PAC ID: 4587576814 Enrollment ID: O20031105000541 |
News Archive
A team of Italian scientists reported this week that blocking the interaction between urokinase receptor (uPAR) and formyl peptide receptor type 1 (FPR1) suppresses the ability of melanoma cells to migrate, invade through an extracellular matrix, and to burrow through a layer of endothelial cells.
Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda's screening assay for the early detection of cancer
Research by a team of scientists from Cologne, Munich and Mainz has shown an unprecedented degree of connectivity reorganization in newly-generated hippocampal neurons in response to experience, suggesting their direct contribution to the processing of complex information in the adult brain.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
› Verified 7 days ago
| Entity Name | Cook County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588612832 PECOS PAC ID: 2860398088 Enrollment ID: O20031209000747 |
News Archive
A team of Italian scientists reported this week that blocking the interaction between urokinase receptor (uPAR) and formyl peptide receptor type 1 (FPR1) suppresses the ability of melanoma cells to migrate, invade through an extracellular matrix, and to burrow through a layer of endothelial cells.
Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda's screening assay for the early detection of cancer
Research by a team of scientists from Cologne, Munich and Mainz has shown an unprecedented degree of connectivity reorganization in newly-generated hippocampal neurons in response to experience, suggesting their direct contribution to the processing of complex information in the adult brain.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
› Verified 7 days ago
| Entity Name | Swedish Covenant Management Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760432348 PECOS PAC ID: 4486556016 Enrollment ID: O20040123000850 |
News Archive
A team of Italian scientists reported this week that blocking the interaction between urokinase receptor (uPAR) and formyl peptide receptor type 1 (FPR1) suppresses the ability of melanoma cells to migrate, invade through an extracellular matrix, and to burrow through a layer of endothelial cells.
Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda's screening assay for the early detection of cancer
Research by a team of scientists from Cologne, Munich and Mainz has shown an unprecedented degree of connectivity reorganization in newly-generated hippocampal neurons in response to experience, suggesting their direct contribution to the processing of complex information in the adult brain.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Priya V Rajan, MD Po Box 601372, Charlotte, NC 28260-1372 Ph: (704) 446-1544 | Dr Priya V Rajan, MD 1025 Morehead Medical Dr, Suite 500, Charlotte, NC 28204-2963 Ph: (704) 446-1544 |
News Archive
A team of Italian scientists reported this week that blocking the interaction between urokinase receptor (uPAR) and formyl peptide receptor type 1 (FPR1) suppresses the ability of melanoma cells to migrate, invade through an extracellular matrix, and to burrow through a layer of endothelial cells.
Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda's screening assay for the early detection of cancer
Research by a team of scientists from Cologne, Munich and Mainz has shown an unprecedented degree of connectivity reorganization in newly-generated hippocampal neurons in response to experience, suggesting their direct contribution to the processing of complex information in the adult brain.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
› Verified 7 days ago
Jackie Alan Lucas, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 450, Charlotte, NC 28204 Phone: 704-446-7800 | |
Lynn Amy Boardman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Dr. Simon Vivian Ward Iii, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1918 Randolph Rd, Suite 670, Charlotte, NC 28207 Phone: 704-384-1620 Fax: 704-384-1626 | |
Curtis Lee Flood, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6331 Carmel Rd Ste 102, Charlotte, NC 28226 Phone: 980-367-4363 Fax: 704-316-2558 | |
Grant Blanchard, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Roland Pixley, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 400, Charlotte, NC 28204 Phone: 704-446-1700 | |
Katherine Elizabeth Akeley, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 |